Endologix, Inc. (Nasdaq:ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it will host a meeting for financial analysts and investment professionals at 4:15 p.m. ET on Tuesday, October 2, 2018, at The London Hotel NYC, 151 W. 54th St., New York, NY 10019.
The preliminary agenda for the event includes: | |||||||
| 4:15 p.m. – 6:00 p.m. ET | Management strategic and financial presentations, physician presentations, Q&A | ||||||
| 6:00 p.m. – 7:00 p.m. ET | Product showcase of Endologix devices | ||||||
Participants may register for the meeting here. | |||||||
For those unable to attend in person, a live webcast of the presentations will begin at 4:15 p.m. ET, and will be available on the “Investors” section of the Company’s website at www.endologix.com. Following the event, a replay of the presentation and the associated materials will be available on the same site.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the United States. For more information, visit www.endologix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180823005178/en/
Contacts:
Investors
Vaseem Mahboob, 949-595-7200
CFO
